GlassScriptPhysician profile
Brad M Herman
NPI 1760484729
$1,300.87
in general payments reported to CMS, 2019-2025
16 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $252 · 2021: $357 · 2022: $14.65 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $477.50 | 2019-2021 | |
| Revance Therapeutics, INC. | $217.23 | 2025 | Daxxify |
| Amarin Pharma, INC. | $154.03 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $110.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.35 | 2019-2020 | |
| Esperion Therapeutics, INC. | $51.06 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $49.07 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.73 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $27.69 | 2019 | |
| Novo Nordisk INC | $25.17 | 2021 | |
| Merck Sharp & Dohme LLC | $14.74 | 2019 | |
| Heartflow, INC. | $14.65 | 2022 | |
| Glaxosmithkline, LLC. | $13.50 | 2019 | |
| Shire North American Group INC | $13.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.26 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.